ACBM vs GS: Which Stock is Better?
Side-by-side comparison of Acro Biomedical Co., Ltd. and Goldman Sachs Group Inc in 2026
ACBM
Acro Biomedical Co., Ltd.
$0.02
GS
Goldman Sachs Group Inc
$943.37
Key Metrics Comparison
| Metric | ACBM | GS | Winner |
|---|---|---|---|
| Market Cap | $1.33M | $285.58B | GS |
| P/E Ratio | N/A | 18.40 | GS |
| EPS (TTM) | $N/A | $51.27 | GS |
| Revenue Growth | 2.0% | 0.2% | ACBM |
| Gross Margin | 17.8% | 82.9% | GS |
Analyze ACBM
Full quant analysis
Analyze GS
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is ACBM or GS a better investment?
Comparing ACBM and GS: Acro Biomedical Co., Ltd. has a market cap of $1.33M while Goldman Sachs Group Inc has $285.58B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between ACBM and GS?
ACBM (Acro Biomedical Co., Ltd.) and GS (Goldman Sachs Group Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: ACBM or GS?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: ACBM or GS?
ACBM has higher revenue growth at 2.0% vs 0.2% for GS.
Which company is more profitable: ACBM or GS?
Goldman Sachs Group Inc (GS) has higher gross margins at 82.9% compared to 17.8% for ACBM.
Which is the larger company: ACBM or GS?
Goldman Sachs Group Inc (GS) is larger with a market cap of $285.58B compared to $1.33M for ACBM.
Should I buy ACBM or GS in 2026?
Both ACBM and GS have investment merit. ACBM trades at $0.02 while GS trades at $943.37. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between ACBM and GS stock?
Key differences: Market Cap ($1.33M vs $285.58B), P/E Ratio (N/A vs 18.4x), Revenue Growth (2.0% vs 0.2%), Gross Margin (17.8% vs 82.9%).